Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective trial of leflunomide for immunoglobulin A nephropathy
ChiCTR-IPR-14005368Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of leflunomide in IgA nephropathy (IgAN) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: 24-hour proteinuria, Urine red blood cells and 3 more. Planned start Oct 2014; status: not yet recruiting.
02
Drugs
leflunomide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR-IPR-14005368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005368.